RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 103 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,731,776 | +110.4% | 337,264 | +63.7% | 0.00% | +50.0% |
Q2 2023 | $3,675,664 | 0.0% | 206,035 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $3,675,664 | +199.1% | 206,035 | +388.3% | 0.00% | +100.0% |
Q4 2022 | $1,228,777 | -99.8% | 42,197 | +41.0% | 0.00% | – |
Q3 2022 | $733,459,000 | +222.4% | 29,937 | -45.4% | 0.00% | – |
Q2 2022 | $227,515,000 | -32.9% | 54,823 | +86.3% | 0.00% | – |
Q1 2022 | $339,045,000 | +15.4% | 29,431 | 0.0% | 0.00% | – |
Q4 2021 | $293,722,000 | -10.8% | 29,431 | +16.7% | 0.00% | – |
Q3 2021 | $329,309,000 | -33.3% | 25,215 | 0.0% | 0.00% | – |
Q2 2021 | $493,709,000 | +121.1% | 25,215 | +140.2% | 0.00% | – |
Q1 2021 | $223,250,000 | -74.2% | 10,496 | -64.0% | 0.00% | – |
Q4 2020 | $865,916,000 | +25.0% | 29,126 | -8.9% | 0.00% | – |
Q3 2020 | $692,660,000 | +62.9% | 31,964 | +67.7% | 0.00% | – |
Q2 2020 | $425,104,000 | – | 19,063 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |